Table 1.

Celecoxib randomized clinical add-on trials.

Authors	Study design	Participants	Treatment duration	Celecoxib doses	Antipsychotics	Major findings
Müller et al. 2002 [108]	Double-blind, randomized, placebo-controlled, add-on	N = 50  Schizophrenics Duration of illness not specified (mean 5.9 years)	5 weeks	400 mg/day	Risperidone (flexible dose)	Significant advantage of the COX-2 inhibitor
Rappart and Müller 2004 [109]	Double-blind, randomized, placebo-controlled, add-on	N = 270  Schizophrenics Duration of illness ≤10 years	11 weeks	400 mg/day	Risperidone (flexible dose)	No advantage on the COX-2 inhibitor
Rapaport et al. 2005 [110]	Double-blind, randomized, placebo-controlled, add-on	N = 38  Schizophrenics Continuously ill (mean 20 years)	8 weeks	400 mg/day	Risperidone or olanzapine (constant dose)	No advantage on the COX-2 inhibitor
Zhang et al. 2006 [111]	Double-blind, randomized, placebo-controlled, add-on	N = 40  First manifestation schizophrenia	12 weeks	400 mg/day	Risperidone (flexible dose)	Significant advantage of the COX-2 inhibitor
Akhondzadeh et al. 2007 [112]	Double-blind, randomized, placebo-controlled, add-on	N = 60  Active phase of chronic schizophrenia	8 weeks	400 mg/day	Risperidone (flexible dose)	Significant advantage of the COX-2 inhibitor
Müller et al. 2010 [113]	Double-blind, randomized, placebo-controlled, add-on	N = 49  First manifestation schizophrenia	6 weeks	400 mg/day	Amisulpride (flexible dose)	Significant advantage of the COX-2 inhibitor

Adapted from [114].